Inventors & Scientific Advisors:

Christina Lee Chung, MD, Department of Dermatology, Drexel University College of Medicine

Ibiyonu Lawrence, MD, Department of Internal Medicine, Drexel University College of Medicine

Christian Sell, PhD, Department of Pathology, Drexel University College of Medicine

Company Founder:

Steven Davis - An accomplished entrepreneur with a 20-year career in growing and managing medical device startups. Steve has significant and diverse experience in all facets of medical devices, including product design and enhancement, process and manufacturing engineering, team building, finance, sales and marketing, regulatory requirements, and quality. Steve holds a B.A. from Baylor University.

Markets:

OTC / Cosmetics: Our platform technology can immediately be sold in its current formulation as an anti-aging cream to consumers through distributors and cosmetic stores, or it can be sublicensed to top cosmetic companies as an additive for their products to improve performance.

Medical Products / Therapeutic: Our technology can be adapted to different formulas and doses of rapamycin to treat specific indications, including various dermal disorders and potentially medical issues associated with wounds. This opens up the potential to sublicense to other companies focused on treating skin disorders or wound care and prevention, based on results of clinical studies to be performed.

Technology Platform:

Rapa Cream: Rapamycin is an extraordinary compound isolated from the soil of Easter Island, produced by bacteria in the soil to inhibit the growth of yeast and fungi. The compound inhibits growth of human cells and has been FDA-approved as an immunosuppressant. We have conducted a pilot clinical study at Drexel with topical administration of the low-dose rapamycin cream in about thirty patients ages 40-80 across ethnicities. We have demonstrated that rapamycin does not systemically absorb when administered topically testing serum levels in patients after 6-8 months of continued daily use.